• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

如何对雷诺现象进行分类。73例患者的长期随访研究。

How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.

作者信息

Priollet P, Vayssairat M, Housset E

机构信息

Chair of Clinical Medicine and Vascular Pathology, Hôpital Broussais, Paris, France.

出版信息

Am J Med. 1987 Sep;83(3):494-8. doi: 10.1016/0002-9343(87)90760-1.

DOI:10.1016/0002-9343(87)90760-1
PMID:3661586
Abstract

Raynaud's phenomenon without an underlying cause was diagnosed in 96 consecutive patients in 1978 to 1979. Seventy-three patients were available for long-term follow-up. They were classified on initial evaluation as having primary Raynaud's phenomenon (49 patients) when no clinical, laboratory, or serologic abnormality was detected, and as having suspected secondary Raynaud's phenomenon when at least one finding was abnormal. Re-evaluation was performed in 1984 to 1985 after an average duration of Raynaud's phenomenon of 14.9 +/- 12 years. The average duration of the follow-up from initial to final evaluation was 4.7 +/- 1 years. On final evaluation, none of the 49 patients with an initial diagnosis of primary Raynaud's phenomenon had evidence of secondary Raynaud's phenomenon, whereas 14 of the 24 patients with suspected secondary Raynaud's phenomenon had a definite diagnosis. Among them, there were 13 connective tissue diseases. The study proved that Raynaud's phenomenon without an underlying cause must be followed up for more than two years, contrary to what was recommended previously, before it can be rightly diagnosed as primary Raynaud's phenomenon. Moreover, the results suggested that, in order to distinguish early primary Raynaud's phenomenon from suspected secondary Raynaud's phenomenon, a simple and noninvasive evaluation is sufficient. In this study, the evaluation included history and clinical examination, tests for antinuclear antibodies, radiography of hands, chest roentgenography, and nailfold capillary microscopy.

摘要

1978年至1979年,对96例无潜在病因的雷诺现象患者进行了诊断。其中73例患者可供长期随访。在初始评估时,当未检测到临床、实验室或血清学异常时,将49例患者分类为原发性雷诺现象;当至少有一项检查结果异常时,则分类为疑似继发性雷诺现象。在雷诺现象平均持续14.9±12年后,于1984年至1985年进行了重新评估。从初始评估到最终评估的平均随访时间为4.7±1年。在最终评估中,最初诊断为原发性雷诺现象的49例患者均无继发性雷诺现象的证据,而24例疑似继发性雷诺现象的患者中有14例得到明确诊断,其中有13例为结缔组织病。该研究证明,与之前的建议相反,无潜在病因的雷诺现象必须随访两年以上,才能正确诊断为原发性雷诺现象。此外,结果表明,为了区分早期原发性雷诺现象和疑似继发性雷诺现象,简单的非侵入性评估就足够了。在本研究中,评估包括病史和临床检查、抗核抗体检测、手部X线检查、胸部X线检查和甲襞毛细血管显微镜检查。

相似文献

1
How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.如何对雷诺现象进行分类。73例患者的长期随访研究。
Am J Med. 1987 Sep;83(3):494-8. doi: 10.1016/0002-9343(87)90760-1.
2
[Raynaud's phenomena: diagnostic and treatment study].[雷诺现象:诊断与治疗研究]
Rev Prat. 1998 Oct 1;48(15):1659-64.
3
[Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].[内科继发性雷诺现象的病因学概况。关于121例患者]
J Med Vasc. 2018 Feb;43(1):29-35. doi: 10.1016/j.jdmv.2017.11.005. Epub 2017 Dec 20.
4
Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon.甲襞毛细血管镜检查在雷诺现象筛查与诊断中的应用
Angiology. 1994 Jan;45(1):37-42. doi: 10.1177/000331979404500105.
5
Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.原发性雷诺现象(雷诺病)向结缔组织病的演变。
Arthritis Rheum. 1985 Jan;28(1):87-92. doi: 10.1002/art.1780280114.
6
Raynaud's features in childhood. Clinical, immunological and capillaroscopic study.儿童雷诺现象。临床、免疫学及毛细血管镜检查研究。
J Mal Vasc. 1992;17(4):273-6.
7
[Minimal work-up for Raynaud syndrome: a consensus report. Microcirculation working group of the Société française de médecine vasculaire].[雷诺综合征的最小化检查:一份共识报告。法国血管医学协会微循环工作组]
Ann Dermatol Venereol. 2013 Aug-Sep;140(8-9):549-54. doi: 10.1016/j.annder.2013.02.010. Epub 2013 Apr 11.
8
The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.内皮素-1及特定细胞因子在与系统性结缔组织病相关的雷诺现象发病机制中的作用。
Int Angiol. 2006 Jun;25(2):221-7.
9
Occlusive digital artery disease in patients with Raynaud's phenomenon.雷诺现象患者的闭塞性指动脉疾病。
Am J Med. 1984 Dec;77(6):995-1001. doi: 10.1016/0002-9343(84)90178-5.
10
Raynaud's phenomenon.雷诺现象
Br J Hosp Med (Lond). 2019 Nov 2;80(11):658-664. doi: 10.12968/hmed.2019.80.11.658.

引用本文的文献

1
Extended Periarterial Sympathectomy: Evaluation of Long-term Outcomes.扩大动脉周围交感神经切除术:长期疗效评估
Hand (N Y). 2018 Jul;13(4):395-402. doi: 10.1177/1558944717715119. Epub 2017 Jun 23.
2
Fludarabine Treatment of Patient with Chronic Lymphocytic Leukemia Induces a Digital Ischemia.氟达拉滨治疗慢性淋巴细胞白血病患者诱发指端缺血。
Case Rep Hematol. 2016;2016:7362791. doi: 10.1155/2016/7362791. Epub 2016 Nov 3.
3
Calcium channel blockers for primary Raynaud's phenomenon.用于原发性雷诺现象的钙通道阻滞剂。
Cochrane Database Syst Rev. 2016 Feb 25;2(2):CD002069. doi: 10.1002/14651858.CD002069.pub5.
4
Predictive value of nailfold capillaroscopy in the diagnosis of connective tissue diseases.甲襞毛细血管镜检查在结缔组织病诊断中的预测价值。
Clin Rheumatol. 1996 Mar;15(2):148-53. doi: 10.1007/BF02230332.
5
Clinical aspects of systemic sclerosis (scleroderma).系统性硬化症(硬皮病)的临床方面
Ann Rheum Dis. 1991 Nov;50 Suppl 4(Suppl 4):854-61. doi: 10.1136/ard.50.suppl_4.854.
6
Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases.
Clin Rheumatol. 1992 Mar;11(1):76-80. doi: 10.1007/BF02207089.
7
Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism.
J Endocrinol Invest. 1992 Jan;15(1):49-51. doi: 10.1007/BF03348657.
8
Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities. A six-year follow-up study.
Clin Rheumatol. 1992 Dec;11(4):536-41. doi: 10.1007/BF02283115.
9
Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations.
Clin Rheumatol. 1992 Sep;11(3):356-63. doi: 10.1007/BF02207193.